Shenzhen Salubris Pharmaceuticals Co Ltd (002294) - Total Liabilities
Based on the latest financial reports, Shenzhen Salubris Pharmaceuticals Co Ltd (002294) has total liabilities worth CN¥2.05 Billion CNY (≈ $300.34 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shenzhen Salubris Pharmaceuticals Co Ltd - Total Liabilities Trend (2006–2024)
This chart illustrates how Shenzhen Salubris Pharmaceuticals Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Shenzhen Salubris Pharmaceuticals Co Ltd to evaluate short-term liquidity relative to the company's equity base.
Shenzhen Salubris Pharmaceuticals Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shenzhen Salubris Pharmaceuticals Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Scout24 AG
XETRA:G24
|
Germany | €737.38 Million |
|
Shenzhen Zhongjin Lingnan Nonfemet Co Ltd
SHE:000060
|
China | CN¥31.14 Billion |
|
Trina Solar Co Ltd
SHG:688599
|
China | CN¥90.54 Billion |
|
Firefly Aerospace Inc. Common Stock
NASDAQ:FLY
|
USA | $387.11 Million |
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
|
China | CN¥851.65 Million |
|
Ameris Bancorp
NASDAQ:ABCB
|
USA | $23.08 Billion |
|
Kunshan Kinglai Hygienic Materials Co Ltd
SHE:300260
|
China | CN¥3.37 Billion |
|
Turkcell Iletisim Hizmetleri AS
NYSE:TKC
|
USA | $248.39 Billion |
Liability Composition Analysis (2006–2024)
This chart breaks down Shenzhen Salubris Pharmaceuticals Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 002294 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shenzhen Salubris Pharmaceuticals Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shenzhen Salubris Pharmaceuticals Co Ltd (2006–2024)
The table below shows the annual total liabilities of Shenzhen Salubris Pharmaceuticals Co Ltd from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.71 Billion ≈ $250.71 Million |
+27.74% |
| 2023-12-31 | CN¥1.34 Billion ≈ $196.27 Million |
-24.59% |
| 2022-12-31 | CN¥1.78 Billion ≈ $260.26 Million |
+48.43% |
| 2021-12-31 | CN¥1.20 Billion ≈ $175.34 Million |
-9.69% |
| 2020-12-31 | CN¥1.33 Billion ≈ $194.16 Million |
+24.36% |
| 2019-12-31 | CN¥1.07 Billion ≈ $156.12 Million |
+3.22% |
| 2018-12-31 | CN¥1.03 Billion ≈ $151.25 Million |
+46.43% |
| 2017-12-31 | CN¥705.86 Million ≈ $103.29 Million |
-34.28% |
| 2016-12-31 | CN¥1.07 Billion ≈ $157.17 Million |
+55.38% |
| 2015-12-31 | CN¥691.25 Million ≈ $101.15 Million |
-16.51% |
| 2014-12-31 | CN¥827.95 Million ≈ $121.16 Million |
+62.87% |
| 2013-12-31 | CN¥508.36 Million ≈ $74.39 Million |
+35.92% |
| 2012-12-31 | CN¥374.02 Million ≈ $54.73 Million |
+20.45% |
| 2011-12-31 | CN¥310.52 Million ≈ $45.44 Million |
+0.33% |
| 2010-12-31 | CN¥309.50 Million ≈ $45.29 Million |
+108.30% |
| 2009-12-31 | CN¥148.59 Million ≈ $21.74 Million |
+1.98% |
| 2008-12-31 | CN¥145.70 Million ≈ $21.32 Million |
+32.48% |
| 2007-12-31 | CN¥109.98 Million ≈ $16.09 Million |
+110.74% |
| 2006-12-31 | CN¥52.19 Million ≈ $7.64 Million |
-- |
About Shenzhen Salubris Pharmaceuticals Co Ltd
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also develops Sacubit… Read more